NCT07054242 2025-10-01
A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)
Yantai Yuhuangding Hospital
Phase 2 Not yet recruiting
Yantai Yuhuangding Hospital
Sun Yat-sen University
Fudan University
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Shanghai Minimally Invasive Surgery Center